Related references
Note: Only part of the references are listed.Dexamethasone-mediated inhibition of Notch signalling blocks the interaction of leukaemia and mesenchymal stromal cells
Helal Mohammed Mohammed Ahmed et al.
BRITISH JOURNAL OF HAEMATOLOGY (2022)
Pictilisib Enhances the Antitumor Effect of Doxorubicin and Prevents Tumor-Mediated Bone Destruction by Blockade of PI3K/AKT Pathway
Chao Liang et al.
FRONTIERS IN ONCOLOGY (2021)
The multiple myeloma microenvironment is defined by an inflammatory stromal cell landscape
Madelon M. E. de Jong et al.
NATURE IMMUNOLOGY (2021)
The microenvironment in myeloma
Oliver C. Lomas et al.
CURRENT OPINION IN ONCOLOGY (2020)
A Comparative Analysis of Multipotent Mesenchymal Stromal Cells derived from Different Sources, with a Focus on Neuroregenerative Potential
Yuriy Petrenko et al.
SCIENTIFIC REPORTS (2020)
The PI3K-AKT network at the interface of oncogenic signalling and cancer metabolism
Gerta Hoxhaj et al.
NATURE REVIEWS CANCER (2020)
IFNβ enhances mesenchymal stromal (Stem) cells immunomodulatory function through STAT1-3 activation and mTOR-associated promotion of glucose metabolism
Tiziana Vigo et al.
CELL DEATH & DISEASE (2019)
Impact of c-MYC expression on proliferation, differentiation, and risk of neoplastic transformation of human mesenchymal stromal cells
Svitlana Melnik et al.
STEM CELL RESEARCH & THERAPY (2019)
The Pattern of Mesenchymal Stem Cell Expression Is an Independent Marker of Outcome in Multiple Myeloma
Carolina Schinke et al.
CLINICAL CANCER RESEARCH (2018)
Mesenchymal stem cells in multiple myeloma: a therapeutical tool or target?
Song Xu et al.
LEUKEMIA (2018)
PI3K/AKT/mTOR pathway in multiple myeloma: from basic biology to clinical promise
Vijay Ramakrishnan et al.
LEUKEMIA & LYMPHOMA (2018)
Mesenchymal stromal cells from myelodysplastic and acute myeloid leukemia patients display in vitro reduced proliferative potential and similar capacity to support leukemia cell survival
Giulia Corradi et al.
STEM CELL RESEARCH & THERAPY (2018)
A phase Ib study of pictilisib (GDC-0941) in combination with paclitaxel, with and without bevacizumab or trastuzumab, and with letrozole in advanced breast cancer
Patrick Schoffski et al.
BREAST CANCER RESEARCH (2018)
Novel phosphatidylinositol 3-kinase inhibitor BKM120 enhances the sensitivity of multiple myeloma to bortezomib and overcomes resistance
Wenjun Yu et al.
LEUKEMIA & LYMPHOMA (2017)
Lenalidomide restores the osteogenic differentiation of bone marrow mesenchymal stem cells from multiple myeloma patients via deactivating Notch signaling pathway
Juan Guo et al.
ONCOTARGET (2017)
A Pan-Cancer Proteogenomic Atlas of PI3K/AKT/mTOR Pathway Alterations
Yiqun Zhang et al.
CANCER CELL (2017)
Functional inhibition of mesenchymal stromal cells in acute myeloid leukemia
S. Geyh et al.
LEUKEMIA (2016)
Induction of miR-146a by multiple myeloma cells in mesenchymal stromal cells stimulates their pro-tumoral activity
Kim De Veirman et al.
CANCER LETTERS (2016)
The effect of the PI3K inhibitor BKM120 on tumour growth and osteolytic bone disease in multiple myeloma
Sally Martin et al.
LEUKEMIA RESEARCH (2015)
c-Myc plays part in drug resistance mediated by bone marrow stromal cells in acute myeloid leukemia
Bing Xia et al.
LEUKEMIA RESEARCH (2015)
Activation of PI3K/Akt/mTOR signaling in the tumor stroma drives endocrine therapy-dependent breast tumor regression
Maria Laura Polo et al.
ONCOTARGET (2015)
The effect of the dual PI3K and mTOR inhibitor BEZ235 on tumour growth and osteolytic bone disease in multiple myeloma
Zhen Ying Gan et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2015)
Comprehensive characterization of four different populations of human mesenchymal stem cells as regards their immune properties, proliferation and differentiation
Xiuying Li et al.
INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE (2014)
Discovery and saturation analysis of cancer genes across 21 tumour types
Michael S. Lawrence et al.
NATURE (2014)
The PI3K inhibitor GDC-0941 combines with existing clinical regimens for superior activity in multiple myeloma
V. Munugalavadla et al.
ONCOGENE (2014)
Evidences of Early Senescence in Multiple Myeloma Bone Marrow Mesenchymal Stromal Cells
Thibaud Andre et al.
PLOS ONE (2013)
A novel selective small-molecule PI3K inhibitor is effective against human multiple myeloma in vitro and in vivo
J. Glauer et al.
BLOOD CANCER JOURNAL (2013)
Multiple Myeloma Mesenchymal Stem Cells: Characterization, Origin, and Tumor-Promoting Effects
Michaela R. Reagan et al.
CLINICAL CANCER RESEARCH (2012)
Mesenchymal stromal cells of myelodysplastic syndrome and acute myeloid leukemia patients have distinct genetic abnormalities compared with leukemic blasts
Olga Blau et al.
BLOOD (2011)
Distinct transcriptional profiles characterize bone microenvironment mesenchymal cells rather than osteoblasts in relationship with multiple myeloma bone disease
Katia Todoerti et al.
EXPERIMENTAL HEMATOLOGY (2010)
Survivin is upregulated in myeloma cell lines cocultured with mesenchymal stem cells
Xiaofang Wang et al.
LEUKEMIA RESEARCH (2010)
Bone marrow microenvironment and the identification of new targets for myeloma therapy
K. Podar et al.
LEUKEMIA (2009)
Mesenchymal stem cells from multiple myeloma patients display distinct genomic profile as compared with those from normal donors
M. Garayoa et al.
LEUKEMIA (2009)
Management of Complications in Multiple Myeloma
Evangelos Terpos et al.
SEMINARS IN HEMATOLOGY (2009)
Abnormal cytokine production by bone marrow stromal cells of multiple myeloma patients in response to RPMI8226 myeloma cells
Barbara Zdzisinska et al.
ARCHIVUM IMMUNOLOGIAE ET THERAPIAE EXPERIMENTALIS (2008)
Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets
Teru Hideshima et al.
NATURE REVIEWS CANCER (2007)
Bone marrow mesenchymal stem cells are abnormal in multiple myeloma
J. Corre et al.
LEUKEMIA (2007)
Mesenchymal stem cell abnormalities in patients with multiple myeloma
Laurent Garderet et al.
LEUKEMIA & LYMPHOMA (2007)
Exploiting the PI3K/AKT pathway for cancer drug discovery
BT Hennessy et al.
NATURE REVIEWS DRUG DISCOVERY (2005)
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma
PG Richardson et al.
BLOOD (2002)
Share Paper
